Качественная клиническая практика (Jul 2023)
Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis
Abstract
Objective. Comparative pharmacoeconomic evaluation of upadacitinib, baricitinib and dupilumab for the treatment of moderate to severe atopic dermatitis.Materials and methods. Study design — retrospective. Pharmacoeconomic analysis method — cost-effectiveness analysis, budget impact analysis. Data sources. On the effectiveness of compared alternatives — meta-analysis of randomized clinical trials for the compared drugs, clinical recommendations; on the cost of drugs — the state register of maximum selling prices.Results. Lowest cost-effectiveness (CER) values for both EASI-75 and EASI-90 responses were for upadacitinib. For upadacitinib 15 mg/day, the cost of achieving EASI-75 and EASI-90 responses was reduced by 63.9 and 70.3%, respectively compared to dupilumab and by 44.2 and 46.8% compared to baricitinib. For upadacitinib 30 mg/day, the reduction in the cost of achieving the effect compared to dupilumab will be, respectively, 40.8 and 56.2%, and compared with baricitinib — 8,5 and 21.4%. The budget impact analysis (BIA) showed that the increase in the share of upadacitinib from 15 to 35%, and the proportion of baricitinib — from 5 to 10% due to a decrease in the proportion of patients, receiving dupilumab will reduce the budget impact in the treatment of patients with severe atopic dermatitis on the scale of the Russian Federation by a total of 11.6% (RUB 1.25 billion) with a single-step change from the first year and by 7.9% (RUB 0.86 billion) with a gradual change over 3 years. An analysis of missed opportunities showed that if the share of upadacitinib changes to 35% 741 patients can be additionally provided with therapy in the first year, 629 patients in the second year and 567 patients in the third (with a target population size of 4929 patients).Conclusion. Increasing the share of upadacitinib will not only significantly reduce the burden on the budget of the healthcare system by refusing to use more expensive dupilumab in some patients, but also increase the proportion of patients achieving the goals of therapy in terms of EASI-75 and EASI-90.
Keywords
